Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amplify Transformational Data Sharing ETF (BLOK) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

Amplify Transformational Data Sharing ETFTrade
Regeneron Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Amplify Transformational Data Sharing ETF vs Regeneron Pharmaceuticals Inc — how do they compare? Amplify Transformational Data Sharing ETF trades at $59.06, while Regeneron Pharmaceuticals Inc trades at $794 (market cap $83.19B). The key difference: Regeneron Pharmaceuticals Inc pays a 0.47% dividend while Amplify Transformational Data Sharing ETF pays none, and Regeneron Pharmaceuticals Inc is trading nearer its 52-week high, Amplify Transformational Data Sharing ETF nearer its low. Which is the better fit depends on your goals.

BLOKREGN
52-Week High
$74.10$812.27
52-Week Low
$47.36$545.94
Market Cap
$83.19B
Sector
Health
Enterprise Value
$77.90B
Dividend Yield
0.47%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amplify Transformational Data Sharing ETF

BLOK trades at $59.89 with minimal daily movement (+0.4%). Technical indicators show a bearish trend with all 13 moving averages signaling sell, while oscillators remain neutral. The stock faces resistance at $60 and support at $59. Recent news highlights the ETF's diversified blockchain economy exposure and inclusion of SpaceX shares following its historic IPO.

The outlook remains cautious due to strong bearish technical signals and sector volatility. Investment opportunity lies in diversified blockchain economy exposure, but risks include market sentiment shifts and competitive ETF landscape. Wall Street sentiment appears mixed with technical weakness offset by strategic positioning in growing sectors.

Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals (REGN) trades at $784.36, up 1.59% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong profitability with a net income margin of 27.86% and has beaten EPS estimates in recent quarters. However, multiple class-action lawsuits filed in August 2026 allege inadequate clinical-trial risk disclosures, creating investor uncertainty amid solid financial performance.

Outlook remains supported by earnings momentum and analyst buy ratings, but legal risks and high valuation multiples pose near-term headwinds. Investment opportunity hinges on legal resolution and sustained drug pipeline success, while risks include trial setbacks and regulatory scrutiny.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Amplify Transformational Data Sharing ETF

The fund is an actively managed ETF that seeks to provide total return by investing at least 80% of its net assets in the equity securities of companies actively involved in the development and utilization of "transformational data sharing technologies". It may invest in non-US equity securities, including depositary receipts.

Read more on BLOK

About Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases

Read more on REGN